Results 151 to 160 of about 1,646,961 (327)

Bone-Marrow-Derived Mesenchymal Stromal Cells (MSC) from Diabetic and Nondiabetic Rats Have Similar Therapeutic Potentials

Arquivos Brasileiros de Cardiologia
Background: Diabetes mellitus is a severe chronic disease leading to systemic complications, including cardiovascular dysfunction. Previous cell therapy studies have obtained promising results with the use bone marrow mesenchymal stromal cells derived ...
Vitória Santório de São José, Gustavo Monnerat, Barbara Guerra, Bruno Dias Paredes, Tais Hanae Kasai-Brunswick, Antonio Carlos Campos de Carvalho, Emiliano Medei   +6 more
doaj   +1 more source

FDA Cell therapies and tissue-based products: a public workshop on generating scientific evidence to facilitate development (from Catapult's regulatory round-up for December 2024)

The FDA’s CBER OTP is hosting a virtual scientific public workshop on 25th February 2025, titled “Cell Therapies and Tissue-based Products: A Public Workshop on Generating Scientific Evidence to Facilitate Development.” The purpose of the workshop is to identify and discuss the current state of the science, development, and regulation for cellular ...
openaire   +2 more sources

The Hepatocellular Hypoxia Criteria:2’Nitroimidazole Effect on Hepatocyte Carbohydrate Metabolizing Enzymes [PDF]

, 2008
Aim: to understand the 2’-nitroimidazole induced hypoxia and liver cell interaction, we proposed a “Hapatocellular Hypoxia Criteria”.
Rakesh Sharma
core   +1 more source

Genetically‑modified stem cells in treatment of human diseases: Tissue kallikrein (KLK1)‑based targeted therapy (Review)

, 2018
Marina Devetzi, Maria Goulielmaki, Nicolas Khoury, Demetrios�� Spandidos, Georgia Sotiropoulou, Ioannis Christodoulou, Vassilis Zoumpourlis   +6 more
openalex   +2 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Advances in combining gene therapy with cell and tissue engineering-based approaches to enhance healing of the meniscus [PDF]

, 2016
Magali Cucchiarini, Amy L. McNulty, Robert L. Mauck, Lori A. Setton, Farshid Guilak, Henning Madry   +5 more
openalex   +1 more source

Cytoplasmic p21 promotes stemness of colon cancer cells via activation of the NFκB pathway

Molecular Oncology, EarlyView.
Cytoplasmic p21 promotes colorectal cancer stem cell (CSC) features by destabilizing the NFκB–IκB complex, activating NFκB signaling, and upregulating BCL‐xL and COX2. In contrast to nuclear p21, cytoplasmic p21 enhances spheroid formation and stemness transcription factor CD133.
Arnatchai Maiuthed, Kerstin Huebner, Katharina Erlenbach‐Wuensch, Chuanpit Hampel, Daniela Thalheim, Adriana Vial‐Roehe, Bodee Nutho, Susanne Merkel, Arndt Hartmann, Pithi Chanvorachote, Regine Schneider‐Stock   +10 more
wiley   +1 more source

Regenerative Therapies Using Cell Sheet-Based Tissue Engineering for Cardiac Disease [PDF]

, 2011
Yuji Haraguchi, Tatsuya Shimizu, Masayuki Yamato, Teruo Okano   +3 more
openalex   +1 more source

Gene Therapy Based on Mesenchymal Stem Cells Derived from Adipose Tissue for the Treatment of Obesity and Its Metabolic Complications [PDF]

, 2023
Marta Lopez‐Yus, Maria Pilar García-Sobreviela, Raquel del Moral, José M. Arbones-Mainar   +3 more
openalex   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source